Loading...
NPI 1407898232 · Pearl City, HI · Community/Retail Pharmacy
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Longs Drug Stores California LLC is a community/retail pharmacy provider located in Pearl City, Hawaii. This profile covers 10 Medicare and 13 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Longs Drug Stores California LLC |
| Address | 850 Kamehameha Hwy |
| City | Pearl City |
| State | HI |
| ZIP | 96782 |
| Taxonomy | Community/Retail Pharmacy |
| NPI Enumerated | June 13, 2006 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $426K |
| Medicaid | $32.2K |
LONGS DRUG STORES CALIFORNIA LLC’s billing mix is clearly pharmacy-centered and focused on immunization and COVID-19 testing services: its top Medicare revenue drivers are 91322 (COVID-19 vaccine), K1034 (nonprescription self-administered COVID test), and 90694 (influenza vaccine), and its Medicaid activity similarly features 91322, 90471 (vaccine administration), and 90686 (influenza vaccine). The presence of multiple administration codes (90480, G0008, G0009) alongside product codes indicates the operation provides both vaccine products and point-of-care administration rather than only dispensing medications to be used offsite.
Medicare revenue is concentrated: the precomputed top-3 Medicare codes account for 63.5% of this provider's total Medicare revenue, with 91322 contributing 26.9%, K1034 25.0%, and 90694 11.6% of Medicare receipts. This concentration around a small set of vaccination and COVID-test codes suggests most Medicare billing activity is coming from immunization and test distribution services rather than broader clinical procedures.
Medicaid revenue is similarly concentrated around vaccines and immunization services: the top-3 Medicaid codes account for 54.1% of the provider's Medicaid revenue, led by 91322 at 19.6%, 90471 at 18.2%, and 90686 at 16.4%. That split indicates Medicaid activity mirrors Medicare in clinical focus, but at a much smaller absolute scale.
Payer mix is heavily Medicare-weighted: lifetime Medicare revenue is $426K compared with $32.2K in Medicaid, so Medicare dominates the provider’s public-payer footprint. This pattern makes the entity effectively Medicare-centric in scale, with Medicaid representing a modest share of reimbursement volume.
National competitive standing on Medicare shows relatively high ranks for several vaccine- and test-related codes: 91322 ranks #104 of 29357 (100th percentile), K1034 ranks #319 of 30143 (99th percentile), and 90694 ranks #343 of 51679 (99th percentile). Although these ranks place the provider well up the national distribution for those codes, the dataset’s annotation for these entries classifies the volumes as "typical, unremarkable volume for this code," indicating the provider’s activity is notable but not flagged as an extreme outlier in the source data.
State-level competitive standing on Medicaid is more mixed and generally more modest: 91322 ranks #16 of 32 (52th percentile), 90471 ranks #49 of 231 (79th percentile), and 90686 ranks #46 of 183 (75th percentile). These in-state positions suggest the provider participates in Medicaid immunization services at a middle-to-upper tier in some codes but is not consistently dominant across all Medicaid vaccine codes.
Operational signals: very high claim counts for K1034 (9.8K claims on Medicare, $11 avg paid/claim) point to substantial distribution of nonprescription self-administered COVID tests, a low-margin, high-volume activity that drives a quarter of Medicare revenue. Meanwhile, multiple vaccine product codes with mid-to-high average paid/claim values (e.g., 91322 at $143 avg paid/claim, 90694 at $75 avg paid/claim) indicate revenue is also supported by higher-priced vaccine products alongside administration fees.
There are a few noteworthy billing artifacts: in Medicaid S9430 (pharmacy compounding and dispensing services) shows 73 claims but $0 revenue, representing 0.0% of Medicaid revenue and signaling either non-covered billing, denied payments, or zero-dollar reporting for that service line in this dataset. The provider’s long NPI tenure (enumerated 2006-06-13 (~20 years ago)) combined with the concentrated vaccine/test billing profile suggests a stable retail pharmacy operation that has generated episodic, program-driven volume in immunization and COVID testing over time.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
10 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 91322 | This code represents a SARS–CoV–2 vaccine product administered by intramuscular injection to reduce the patient’s risk of contracting COVID–19. The dosage is 50 mcg/0.5 mL. | 810 | $140 | $115.5K |
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 9,770 | $10 | $107.4K |
| 90694 | This code represents a vaccine product administered into the muscle to protect against four strains of influenza (flu). It is an inactivated, adjuvanted, preservative–free vaccine given as a 0.5 mL… | 670 | $80 | $50K |
| 90480 | The provider administers the first or only component of a SARS–CoV–2 (COVID–19) vaccine by intramuscular injection to reduce the patient's risk of contracting COVID–19. | 810 | $40 | $34.7K |
| 90677 | This code represents a vaccine product administered intramuscularly to protect against pneumococcal disease, a bacterial infection. This is a 20–valent vaccine, protecting against 20 strains of the… | 120 | $280 | $34.6K |
| G0008 | Administration of influenza virus vaccine | 1,100 | $30 | $34.2K |
| 90662 | This code represents a flu vaccine product that is a split virus type, contains no preservatives, and has enhanced effectiveness due to a higher antigen content. It is administered as an injection… | 420 | $70 | $30.4K |
| 0134A | N/A | 410 | $40 | $17.7K |
| 90732 | The provider intramuscularly or subcutaneously injects pneumococcal polysaccharide vaccine in an individual two years or older. This vaccine provides protection against meningitis and pneumonia that… | 30 | $130 | $3.7K |
| G0009 | Administration of pneumococcal vaccine | 140 | $10 | $1.4K |
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 10 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
13 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 91322 | This code represents a SARS–CoV–2 vaccine product administered by intramuscular injection to reduce the patient’s risk of contracting COVID–19. The dosage is 50 mcg/0.5 mL. | 50 | $120 | $6.3K |
| 90471 | In this procedure, the provider administers a live attenuated vaccine using a percutaneous, intradermal, subcutaneous, or intramuscular route. | 580 | $10 | $5.8K |
| 90686 | This code represents a vaccine product administered into the muscle to protect against four strains of influenza (flu). It is preservative free, uses split virus technology, and is given as a 0.5 mL… | 290 | $20 | $5.2K |
| 0064A | N/A | 120 | $30 | $4.1K |
| 90480 | The provider administers the first or only component of a SARS–CoV–2 (COVID–19) vaccine by intramuscular injection to reduce the patient's risk of contracting COVID–19. | 50 | $40 | $2.1K |
| 90674 | This code represents a flu vaccine product that protects against four strains of influenza. It is derived from cell cultures, contains no preservatives or antibiotics, and is administered as a 0.5 mL… | 80 | $20 | $1.9K |
| 0012A | N/A | 50 | $40 | $1.9K |
| 0011A | N/A | 60 | $30 | $1.6K |
| 0134A | N/A | 40 | $40 | $1.5K |
| 90656 | This code represents a preservative–free trivalent influenza vaccine product containing split virus components. It is administered into the muscle in a 0.5 mL dosage. | 30 | $20 | $530 |
Showing 1–10 of 13
How this provider's Medicaid billing volume and revenue compare to other Hawaii providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Hawaii median
13 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 90471 | In this procedure, the provider administers a live attenuated vaccine using a percutaneous, intradermal, subcutaneous, or intramuscular route. | 49 | 230 | 140 | $20 | $16.1K |
| 91322 | This code represents a SARS–CoV–2 vaccine product administered by intramuscular injection to reduce the patient’s risk of contracting COVID–19. The dosage is 50 mcg/0.5 mL. | 16 | 30 | 50 | $110 | $7.7K |
| 0012A | N/A | 50 | 90 | 70 | $30 | $5.6K |
| 90686 | This code represents a vaccine product administered into the muscle to protect against four strains of influenza (flu). It is preservative free, uses split virus technology, and is given as a 0.5 mL… | 46 | 180 | 120 | $10 | $4.7K |
| 0011A | N/A | 51 | 90 | 80 | $20 | $4.4K |
| 0064A | N/A | 25 | 100 | 60 | $30 | $3.2K |
| 90480 | The provider administers the first or only component of a SARS–CoV–2 (COVID–19) vaccine by intramuscular injection to reduce the patient's risk of contracting COVID–19. | 27 | 60 | 50 | $30 | $2.8K |
| 0031A | N/A | 22 | 20 | 30 | $20 | $2K |
| 0134A | N/A | 17 | 40 | 30 | $30 | $1.5K |
| 90674 | This code represents a flu vaccine product that protects against four strains of influenza. It is derived from cell cultures, contains no preservatives or antibiotics, and is administered as a 0.5 mL… | 18 | 60 | 50 | $20 | $1.3K |
Showing 1–10 of 13
Other providers in the same ZIP code as Longs Drug Stores California LLC, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| David C. Ching,d.m.d.,llc | HI | Pediatric Dentistry | $0 | $5.1M |
| Apria Healthcare LLC | HI | Durable Medical Equipment & Medical Supplies | $0 | $2.7M |
| Pacific Endoscopy Center, LLC | HI | Ambulatory Surgical Clinic/Center | $610.3K | $2M |
| Jason R. Ching Dds LLC | HI | Dentist | $0 | $2.4M |
| Jojie Reyes | HI | Case Management Registered Nurse | $0 | $824.1K |
| Above And Beyond Case Management | HI | Case Management Registered Nurse | $0 | $475.1K |
| Travis Nishioka | HI | General Practice Dentistry | $0 | $467.1K |
| Pearl Family Dental Care, Inc | HI | General Practice Dentistry | $0 | $421.7K |
| Longs Drug Stores California, L.L.C. | HI | Pharmacy | $278.5K | $30.2K |
| Us Med Urgent Care | HI | Urgent Care Clinic/Center | $0 | $256.1K |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.